US2008193456A1PendingUtilityA1

Therapy-enhancing glucan

75
Assignee: CHEUNG NAI-KONG VPriority: Jan 16, 2001Filed: Feb 25, 2008Published: Aug 14, 2008
Est. expiryJan 16, 2021(expired)· nominal 20-yr term from priority
Inventors:Nai-Kong V. Cheung
A61K 39/39A61K 39/44A61P 43/00A61K 47/36A61K 31/739A61K 31/715A61K 31/716A61K 39/39541C08B 37/0024A61P 35/00A61K 39/39558A61P 37/04A61K 2039/55583
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.

Claims

exact text as granted — not AI-modified
1 - 66 . (canceled) 
     
     
         67 . A composition comprising
 (i) a complement-activating antibody that binds to cancer cells expressing an antigen selected from a group consisting of CD20, GD2, GD3, EGFR and HER2; and   (ii) an orally administered β-glucan,   wherein said β-glucan is determined in one or more assays to have similar or better capability in enhancing cancer therapy as compared to barley glucan,   wherein said assays comprise orally administering said β-glucan to a subject in an amount effective to enhance the antitumor activity of an anti-tumor antibody,   wherein the % tumor growth seen with a combination of said β-glucan and anti-tumor antibody is similar to or less than that of a combination of said barley glucan and anti-tumor antibody.   
     
     
         68 . The composition of  claim 67  wherein the barley glucan has an average molecular weight of 210 kilodaltons. 
     
     
         69 . The composition of  claim 67  wherein said complement-activating antibody is a monoclonal antibody. 
     
     
         70 . The composition of  claim 67  wherein said complement-activating antibody is capable of activating antibody-dependent cell-mediated cytotoxicity. 
     
     
         71 . The composition of  claim 67  wherein the cancer cells expressing CD20 are those of non-Hodgkins's lymphoma, Hodgkins's lymphoma or Epstein-Barr related lymphoma. 
     
     
         72 . The composition of  claim 67  wherein the cancer cells expressing GD2 are those of neuroblastoma. 
     
     
         73 . The composition of  claim 67  wherein the cancer cells expressing GD3 are those of melanoma. 
     
     
         74 . The composition of  claim 67  wherein the cancer cells expressing EGFR are those of epidermoid carcinoma. 
     
     
         75 . The composition of  claim 67  wherein the cancer cells expressing HER2 are those of breast cancer. 
     
     
         76 . A composition comprising
 (i) a complement-activating antibody that binds to cancer cells selected from a group consisting of neuroblastoma cells, melanoma cells, non-Hodgkin's lymphoma cells, Hodgkin's lymphoma cells, Epstein-Barr related lymphoma cells, epidermoid carcinoma cells and breast cancer cells; and   (ii) an orally administered β-glucan,   wherein said β-glucan is determined in one or more assays to have similar or better capability in enhancing cancer therapy as compared to barley glucan,   wherein said assays comprise orally administering said β-glucan to a subject in an amount effective to enhance the antitumor activity of an anti-tumor antibody,   wherein the % tumor growth seen with a combination of said β-glucan and anti-tumor antibody is similar to or less than that of a combination of said barley glucan and anti-tumor antibody.   
     
     
         77 . The composition of  claim 76  wherein the barley glucan has an average molecular weight of 210 kiloDaltons. 
     
     
         78 . The composition of  claim 76  wherein said complement-activating antibody is a monoclonal antibody. 
     
     
         79 . The composition of  claim 76  wherein said complement-activating antibody is capable of activating antibody-dependent cell-mediated cytotoxicity. 
     
     
         80 . The composition of  claim 76  wherein said complement-activating antibody is directed to CD20. 
     
     
         81 . The composition of  claim 76  wherein said complement-activating antibody is directed to GD2. 
     
     
         82 . The composition of  claim 76  wherein said complement-activating antibody is directed to GD3. 
     
     
         83 . The composition of  claim 76  wherein said complement-activating antibody is directed to EGFR. 
     
     
         84 . The composition of  claim 76  wherein said complement-activating antibody is directed to HER2. 
     
     
         85 . A method of enhancing the anti-tumor effect of a complement-activating antibody administered to a subject, comprising orally administering a β-glucan in an amount effective to enhance the anti-tumor effect of said antibody,
 wherein the complement-activating antibody binds to cancer cells expressing an antigen selected from a group consisting of CD20, GD2, GD3, EGFR and HER2,   wherein said β-glucan is determined in one or more assays to have similar or better capability in enhancing cancer therapy as compared to barley glucan,   wherein said assays comprise orally administering said β-glucan to a subject in an amount effective to enhance the antitumor activity of an anti-tumor antibody,   wherein the % tumor growth seen with a combination of said β-glucan and anti-tumor antibody is similar to or less than that of a combination of said barley glucan and anti-tumor antibody.   
     
     
         86 . The method of  claim 85  wherein the barley glucan has an average molecular weight of 210 kiloDaltons. 
     
     
         87 . The method of  claim 85  wherein said complement-activating antibody is a monoclonal antibody. 
     
     
         88 . The method of  claim 85  wherein said complement-activating antibody is capable of activating antibody-dependent cell-mediated cytotoxicity. 
     
     
         89 . The method of  claim 85  wherein the cancer cells are selected from a group consisting of neuroblastoma cells, melanoma cells, non-Hodgkin's lymphoma cells, Hodgkin's lymphoma cells, Epstein-Barr related lymphoma cells, epidermoid carcinoma cells and breast cancer cells. 
     
     
         90 . The method of  claim 85  wherein the subject is a mammal or human. 
     
     
         91 . A method of enhancing the anti-tumor effect of a complement-activating antibody administered to a subject, comprising orally administering a β-glucan in an amount effective to enhance the anti-tumor effect of said antibody,
 wherein said complement-activating antibody binds to cancer cells of neuroblastoma, melanoma, lymphoma, epidermoid carcinoma or breast cancer,   wherein said β-glucan is determined in one or more assays to have similar or better capability in enhancing cancer therapy as compared to barley glucan,   wherein said assays comprise orally administering said β-glucan to a subject in an amount effective to enhance the antitumor activity of an anti-tumor antibody,   wherein the % tumor growth seen with a combination of said β-glucan and anti-tumor antibody is similar to or less than that of a combination of said barley glucan and anti-tumor antibody.   
     
     
         92 . The method of  claim 91  wherein the barley glucan has an average molecular weight of 210 kiloDaltons. 
     
     
         93 . The method of  claim 91  wherein said complement-activating antibody is a monoclonal antibody. 
     
     
         94 . The method of  claim 91  wherein said complement-activating antibody is capable of activating antibody-dependent cell-mediated cytotoxicity. 
     
     
         95 . The method of  claim 91  wherein the lymphoma cells express the antigen CD20. 
     
     
         96 . The method of  claim 91  wherein the neuroblastoma cells express the antigen GD2. 
     
     
         97 . The method of  claim 91  wherein the melanoma cells express the antigen GD3. 
     
     
         98 . The method of  claim 91  wherein the subject is a mammal or human. 
     
     
         99 . The method of  claim 91  wherein the lymphoma cells are selected from a group consisting of non-Hodgkin's lymphoma cells, Hodgkin's lymphoma cells and Epstein-Barr related lymphoma cells.

Join the waitlist — get patent alerts

Track US2008193456A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.